1. THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS. (12th June 2019) Authors: Advani, R.; Bartlett, N.L.; Smith, S.M.; Roschewski, M.; Popplewell, L.; Flinn, I.; Collins, G.; Ghosh, N.; LaCasce, A.; Asch, A.; Kline, J.; Kesevan, M.; Tran, T.; Lynn, J.; Huang, J.; Agoram, B.; Volkmer, J.; Takimoto, C.H.; Chao, M.P.; Mehta, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗